My research focuses on defining the molecular basis of regulation of oncogenic signalling transduction, ribosome synthesis and function in cancer cells. I am currently leading the preclinical studies of targeting ribosome biogenesis in blood cancers and ovarian cancer, using my expertise in cell biology, protein biochemistry, cell signalling and cell metabolism and the use of animal models to investigate the efficacy and mechanisms of targeted therapy in cancer.
Following completion of my PhD in molecular medicine at the University of Auckland, New Zealand, in 2011, I joined the Garvan Institute of Medical Research in Sydney. In 2013, I moved to the Peter MacCallum Cancer Centre, and in early 2023 joined SVI’s DNA Damage & Cancer Therapy.
Key achievements
2010 Merck Young Investigator Award (New Zealand)
2009 University of Auckland (New Zealand); Postgraduate Research Leadership Award, Liggins Institute
Selected publications
Zhu, H., Chan, K. T., Huang, X., Cerra, C., Blake, S., Trigos, A. S., Anderson, D., Creek, D. J., De Souza, D. P., Wang, X., Fu, C., Jana, M., Sanij, E., Pearson, R. B.*, & Kang, J.* (2022, Jun 27). Cystathionine-β-synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation. Elife, 11. https://doi.org/10.7554/eLife.71929 (*co-coresponding author)
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021). Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduction and Targeted Therapy, 6(1), 323. https://doi.org/10.1038/s41392-021-00728-8
Kusnadi, E. P., Trigos, A. S., Cullinane, C., Goode, D. L., Larsson, O., Devlin, J. R., Chan, K. T., De Souza, D. P., McConville, M. J., McArthur, G. A., Thomas, G., Sanij, E., Poortinga, G., Hannan, R. D., Hannan, K. M.*, Kang, J.*, & Pearson, R. B*. (2020). Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis. The EMBO Journal, 39(21), e105111.
Sanij, E., Hannan, K. M., Xuan, J., Yan, S., Ahern, J. E., Trigos, A. S., Brajanovski, N., Son, J., Chan, K. T., Kondrashova, O., Lieschke, E., Wakefield, M. J., Frank, D., Ellis, S., Cullinane, C., Kang, J., Poortinga, G., Nag, P., Deans, A. J., Khanna, K. K., Mileshkin, L., McArthur, G. A., Soong, J., Berns, E., Hannan, R. D., Scott, C. L., Sheppard, K. E., & Pearson, R. B. (2020, May 26). CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nat Commun, 11(1), 2641. https://doi.org/10.1038/s41467-020-16393-4 https://doi.org/https://doi.org/10.15252/embj.2020105111 (*Co-coresponding author)
Ge, C., Huang, H., Huang, F., Yang, T., Zhang, T., Wu, H., Zhou, H., Chen, Q., Shi, Y., Sun, Y., Liu, L., Wang, X., Pearson, R. B.*, Cao, Y.*, Kang, J.*, & Fu, C*. (2019, Sep 24). Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. Proc Natl Acad Sci U S A, 116(39), 19635-19645. https://doi.org/10.1073/pnas.1908998116 (*Co-coresponding author)
Kang, J., Kusnadi, E. P., Ogden, A. J., Hicks, R. J., Bammert, L., Kutay, U., Hung, S., Sanij, E., Hannan, R. D., Hannan, K. M., & Pearson, R. B. (2016, Aug 2). Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription. Oncotarget, 7(31), 48887-48904. https://doi.org/10.18632/oncotarget.10346
ORCID profile: https://orcid.org/0000-0001-9998-4975
Google Scholar profile: https://scholar.google.com.au/citations?user=t6X92QgAAAAJ&hl=en
DNA Damage & Cancer Therapy
We are developing new therapeutic approaches to target drug resistance in ovarian cancer and in the blood cancer multiple myeloma.
Lab head: Associate Professor Elaine Sanij